CLINICAL_TRIALS trial_result · 2026-03-10

Clinical Trial Update: A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Results from a completed study evaluating lorlatinib in patients with non-small cell lung cancer that could not be controlled have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Pfizer | Conditions: Non-Small Cell Lung Carcinoma | Status: COMPLETED | Results posted: 2026-03-10